FDA-approved therapies for the management of Clostridioides difficile infection (CDI) in adults.
Your search for fecal microbiota transplantation returned 26 results
After 6 months following treatment, 90.5% (38 of 42) responders to RBX2660 remained recurrence-free, whereas 85% (17 of 20) patients in the placebo group remained recurrence-free.
Rate of decolonization was highest for patients in the EGD group (85.7%), followed by those in the oral capsule (84.6%), colonoscopy (63.6%), and gastric tube (50%) groups.
USPSTF recommendations on statin use for primary prevention of cardiovascular disease; At-home visual acuity test; A new treatment for major depressive disorder; Novavax COVID-19 vaccine approved for adolescents; And there is an alert regarding the potential risk of transmission of monkeypox through fecal microbiota transplantation.
The FDA has determined the need for additional safety protections after recent studies have documented the presence of monkeypox virus DNA in rectal swabs and/or stool samples from infected individuals.
Among those with irritable bowel syndrome, men and/or those with low Alistipes levels more likely to be nonresponders
Fidaxomicin suggested instead of vancomycin for initial Clostridioides difficile infection episode, recurrent CDI episodes
Authors recommend against probiotics for prevention of CDI; in those with CDI recurrence, FMT recommended to prevent further recurrence
FMT plus anti-PD-1 therapy may change gut microbiome and help overcome drug resistance in some patients with advanced melanoma
90 percent of those undergoing FMT had one-month cure; 4 percent had recurrence within six months